Personalis, Inc. (PSNL): Results of Operations and Financial Condition
Personalis, Inc. (PSNL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 psnl-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Personalis Reports Second Quarter Results and Recent Highlights Clinical test volume surged 199% year-over-year and 33% sequentially to 10,384 tests in Q2 Clinical revenue grew 442% to $2.6 million and overall revenue grew 30
How this was made
The 30-second read
Why it matters
Key trading inputs are (1) large growth in clinical tests and clinical revenue, (2) two Medicare coverage approvals expanding NeXT Personal reimbursement to additional oncology monitoring use cases, and (3) the merger overhang that removes guidance and changes the information cadence.
Market read
Traders can update near-term demand and reimbursement expectations from the Medicare approvals and clinical volume jump, while also adjusting for reduced forward visibility due to the pending acquisition.
What to watch
Merger-related uncertainty (timing, approvals, termination risk) may dominate price action, and the population sequencing revenue declined 9%, suggesting not all revenue lines are accelerating.
Background
This is an SEC 8-K (Item 2.02) with Q2 2026 operating results and strategic highlights, alongside disclosure that Personalis will stop providing financial guidance and will not hold quarterly calls due to the pending Tempus merger.
Ticker impact
Personalis reported Q2 results with clinical revenue up 442% to $2.6M and secured Medicare coverage for NeXT Personal in two new monitoring indications.
Bias upward initially, with volatility driven by merger headlines and reimbursement execution risk.
The filing is a primary disclosure (8-K with operating results) plus two concrete Medicare coverage approvals and a large clinical volume jump, which can re-rate near-term revenue visibility. However, the company also states it will stop issuing financial guidance and holding calls due to the pending Tempus merger, which can reduce incremental clarity for traders.
Market effects
Reimbursement expansion for MRD and oncology monitoring tests can improve demand expectations for advanced genomics providers, supporting the group’s near-term narrative.
Limited direct regional impact; primarily US reimbursement and oncology diagnostics sentiment.
Moderate, as Medicare coverage is US-specific but can influence global payer discussions and clinical adoption narratives.
Counterpoint
The clinical revenue surge may be heavily reimbursement-driven and could normalize if coverage breadth or utilization does not sustain, especially with guidance removed ahead of the Tempus deal.
Key entities
- issuerPersonalis, Inc.
Nasdaq-listed precision oncology genomics company reporting Q2 results and Medicare coverage approvals, with guidance suspended due to pending Tempus merger.
- acquirerTempus AI, Inc.
Named in the merger agreement; transaction is pending and affects Personalis’ guidance and call schedule.
- productNeXT Personal
Personalis’ oncology monitoring test referenced in Medicare coverage approvals and clinical study highlights.
